A new trading day began on Friday, with Prime Medicine Inc (NASDAQ: PRME) stock price up 7.74% from the previous day of trading, before settling in for the closing price of $2.97. PRME’s price has ranged from $2.85 to $9.86 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Meanwhile, its annual earnings per share averaged 22.72%. With a float of $46.57 million, this company’s outstanding shares have now reached $97.38 million.
Let’s look at the performance matrix of the company that is accounted for 234 employees. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 61.20%, while institutional ownership is 39.41%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.72 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.72% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Here are Prime Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 565.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Prime Medicine Inc (NASDAQ: PRME) saw its 5-day average volume 1.35 million, a positive change from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 10.92%. Additionally, its Average True Range was 0.31.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 8.97%, which indicates a significant decrease from 18.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.90% in the past 14 days, which was lower than the 83.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.79, while its 200-day Moving Average is $5.45. Nevertheless, the first resistance level for the watch stands at $3.35 in the near term. At $3.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.69. If the price goes on to break the first support level at $3.00, it is likely to go to the next support level at $2.80. The third support level lies at $2.65 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
With a market capitalization of 452.21 million, the company has a total of 131,161K Shares Outstanding. Currently, annual sales are 0 K while annual income is -198,130 K. The company’s previous quarter sales were 210 K while its latest quarter income was -52,520 K.
